All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Niche APIs By Popular Demand

August 2, 2019
By Felicity Thomas
Article

Pharmaceutical Technology Europe

Pharmaceutical Technology EuropePharmaceutical Technology Europe-08-01-2019
Volume 31
Issue 8
Pages: 28

Rapid change towards industry developing and manufacturing niche APIs is leading to smaller-scale facilities that offer higher containment and flexibility.

Multiple factors are driving growth in the API market. According to market analysis, an increase in the adoption of biologics, rise of high-potency ingredients, blockbuster patent expiration, and an ageing population are some of the influencers to the API market expansion (1).

To find out more about the evolution of APIs, how industry shifts have impacted pharma companies and supply chains, as well as potential trends for the sector in the coming years, Pharmaceutical Technology Europe spoke with James Lawler, head of quality at C2 Pharma.

API evolution

PTE: Could you describe the evolution of APIs in the pharma industry over the past three decades?

Lawler (C2 Pharma): The evolution of APIs has been extraordinary in terms of the number and volumes produced. Most of this period was dominated with large-volume, blockbuster drugs, and many large API facilities were built exclusively for production of these ingredients at multi-ton scales. As many of these APIs came off-patent, the market prices dropped dramatically, and production shifted to Asia where manufacturing costs are much lower.

During the past decade, there has been a rapid change towards the development and manufacturing of niche APIs, which are more potent and are required in different volumes than the blockbusters of the past. The more potent the API is, the less amount is required for the product, and the higher the market price and profitability. This has caused a shift towards building small-scale facilities with higher containment and flexibility requirements. 

Marked rise in issues

PTE: What implications have these hard-to-source products had on pharma companies and the respective supply chains?

Lawler (C2 Pharma): As facilities transition and supply chains shift globally, there has been a marked rise in drug shortages and quality issues. In some cases, manufacturers simply could not get access to a critical API reliably, whereas in others, they could get access, but the quality was not acceptable. 

When these blockbusters fell off patent, prices dropped and generic competition rose, causing many of manufacturers from the United States and European Union to stop making certain APIs, and creating a gap in the supply chain. Then as production transitioned to Asia, there was a drastic increase in quality issues of various kinds. In some cases, Asian API sources did not meet pharmaceutical-grade standards and products with less purity from other industry applications were falsely sold as pharmaceutical-grade. In other instances, facilities were lacking from cleanliness, containment, and suffering from contamination issues. And in the worst cases, documentation and products have even been fully falsified, causing great unrest in the industry. Based on these occurrences, across the industry a hesitance to work with Asian suppliers has grown. This was intensified as many Asian production facilities continued to receive warning letters and import alerts, and multiple recalls were issued.

No doubt, demand for cheaper medicines are partly responsible for fuelling these shortages, but federal regulations have also hindered the progress of API development and production with conflicting demand for low production costs and market pricing. Manufacturers have had little support to meet these demands, forcing them to turn in directions they may not have in the past, even while these same government-funded regulatory agencies are continually identifying and citing poor quality standards within the available options. 

The reality is that programmes need to be supported at both a country and global level to ensure quality, reliability, and transparency of the pharmaceutical supply chain globally. 

Always a place for APIs

PTE: In your opinion, what do you see as being the major trends in APIs for the pharma industry for the coming decade?

Lawler (C2 Pharma): While large-volume APIs for the maintenance of daily conditions (such as hypertension, regulation of cholesterol, acid reflux, etc.) will continue to be important, their demand is expected to decrease over time. This is being driven by US and EU focus on preventing and/or managing conditions with lifestyle changes such as diet, fitness, and weight management. And even in cases where these medicines are still necessary, many of these groups are now avoiding generic medications and preferring to pay for the branded product or a niche product, especially if it has a natural source or input.

While Big Pharma continues to respond to this evolution by moving away from multi-ton blockbusters to lower-volume, higher-potency, and niche APIs, we have also seen an evolution of pharma towards biotech with a drive towards combination, personalized, and cell and gene therapies. And though these types of drugs are much more specific and effective, they are also much more expensive to produce, transport, distribute, and store. 

Over the coming years we expect to see more growth in the development and manufacture of niche APIs, and a continued strategic split as many Big Pharma companies focus on these ‘next-generation’ medicines and abandon conventional chemical API treatments. However, this trend cannot continue forever. The fact remains that the world’s population continues to grow and age rapidly, and biotech cannot cure everything. APIs will always have a place in the medicines market. 

Reference

1. Research and Markets, “Active Pharmaceutical Ingredients (API) Global Market-Forecast to 2025,” Report, May 2019.

Article Details

Pharmaceutical Technology Europe
Vol. 31, No. 8
July 2019
Page: 28

Citation 

When referring to this article, please cite it as F. Thomas, “Niche APIs By Popular Demand,” Pharmaceutical Technology Europe 31 (8) 2019.

 

Download Issue PDF
Articles in this issue

Realizing the Potential of Vaccines
Celebrating in Style
The CDMO Evolution
Niche APIs By Popular Demand
Partnering Up for Success
In Safe Hands
Regulatory Harmony
Tooling Up for Pharma
Raise a Glass to Pharma Vials
Analysis and Purification: Instrumental to BioPharma
One Small Step for Man, One Giant Leap for Pharma Regulators
Farther Than the Eye Can See
Standing the Test of Time
Standing the Test of Time
The Great Divide? Implications of the SPC Waiver
The Great Divide? Implications of the SPC Waiver
Pharmaceutical Technology Europe, August 2019 Issue (PDF)
Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content

A group of antibiotic pill capsules falling. Healthcare and medical 3D illustration background | Image Credit: © James Thew - stock.adobe.com

Personalised Capsule Machine Unveiled by ACG

Christopher Cole
May 20th 2025
Article

ACG partnered with Art of You to launch the world-first Personalised Capsule Machine, enabling on-demand, customized supplement capsules based on individual health data.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

Patrick Lavery
May 19th 2025
Article

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Gold winners award with three stars | Image Credit: © sergign - stock.adobe.com

ISPE Announces Six 2025 FOYA Category Winners

Patrick Lavery
May 15th 2025
Article

Six winners and two honorable mentions were revealed at ISPE’s Europe Annual Conference in London.


Pharmacy, hands and prescription medicine for customer with paper bag for healthcare, drugs and pharmaceutical. Closeup of a pharmacist or medical worker with person in drugstore for retail service | Image Credit: © Azee Jacobs/peopleimages.com - stock.adobe.com

Trump Issues Executive Order Aimed at Reducing Prescription Drug Prices for US Patients

Patrick Lavery
May 13th 2025
Article

According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.

Related Content

A group of antibiotic pill capsules falling. Healthcare and medical 3D illustration background | Image Credit: © James Thew - stock.adobe.com

Personalised Capsule Machine Unveiled by ACG

Christopher Cole
May 20th 2025
Article

ACG partnered with Art of You to launch the world-first Personalised Capsule Machine, enabling on-demand, customized supplement capsules based on individual health data.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

Patrick Lavery
May 19th 2025
Article

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Gold winners award with three stars | Image Credit: © sergign - stock.adobe.com

ISPE Announces Six 2025 FOYA Category Winners

Patrick Lavery
May 15th 2025
Article

Six winners and two honorable mentions were revealed at ISPE’s Europe Annual Conference in London.


Pharmacy, hands and prescription medicine for customer with paper bag for healthcare, drugs and pharmaceutical. Closeup of a pharmacist or medical worker with person in drugstore for retail service | Image Credit: © Azee Jacobs/peopleimages.com - stock.adobe.com

Trump Issues Executive Order Aimed at Reducing Prescription Drug Prices for US Patients

Patrick Lavery
May 13th 2025
Article

According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.